Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CYP2C9 polymorphism and warfarin dose requirements.

× No keyword cloud information.

10 in total

1. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

Authors: A E Rettie; L C Wienkers; F J Gonzalez; W F Trager; K R Korzekwa
Journal: Pharmacogenetics Date: 1994-02

2. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

Authors: C L Crespi; V P Miller
Journal: Pharmacogenetics Date: 1997-06

3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors: G P Aithal; C P Day; P J Kesteven; A K Daly
Journal: Lancet Date: 1999-02-27 Impact factor: 79.321

Review 4. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Authors: J A Goldstein
Journal: Br J Clin Pharmacol Date: 2001-10 Impact factor: 4.335

5. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

Authors: J Taube; D Halsall; T Baglin
Journal: Blood Date: 2000-09-01 Impact factor: 22.113

6. Genetic analysis of the human cytochrome P450 CYP2C9 locus.

Authors: M J Stubbins; L W Harries; G Smith; M H Tarbit; C R Wolf
Journal: Pharmacogenetics Date: 1996-10

7. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

Authors: A S Aynacioglu; J Brockmöller; S Bauer; C Sachse; P Güzelbey; Z Ongen; M Nacak; I Roots
Journal: Br J Clin Pharmacol Date: 1999-09 Impact factor: 4.335

8. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Authors: U Yasar; E Eliasson; M L Dahl; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal: Biochem Biophys Res Commun Date: 1999-01-27 Impact factor: 3.575

9. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

Authors: L S Kaminsky; S M de Morais; M B Faletto; D A Dunbar; J A Goldstein
Journal: Mol Pharmacol Date: 1993-02 Impact factor: 4.436

10. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

Authors: S L Wang; J Huang; M D Lai; J J Tsai
Journal: Pharmacogenetics Date: 1995-02

10 in total

5 in total

CYP2C9 polymorphism and warfarin dose requirements.

1. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9.

2. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.

3. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Review 4. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

5. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.

6. Genetic analysis of the human cytochrome P450 CYP2C9 locus.

7. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.

8. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

9. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.

10. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese.

1. Personalized drug therapy; the genome, the chip and the physician.

2. Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

3. Genetic polymorphism of CYP2C19 in Maharashtrian population.

4. Evaluation of genetic factors for warfarin dose prediction.

5. Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area.